Glaukos reports Phase 4 trial shows iDose TR plus cataract surgery cuts eye pressure more than surgery alone
Glaukos Corporation announced that its Phase 4 randomized, controlled study of iDose TR administered with cataract surgery met the primary efficacy endpoint. At three months the combination reduced mean diurnal intraocular pressure by 11.1 mmHg versus 7.4 mmHg for surgery alone, an incremental 3.6 mmHg reduction (p<0.0001). The trial also met all pre‑specified secondary responder analyses and reported no serious treatment‑related adverse events.
Why it matters
The company said the results reinforce iDose TR’s efficacy and safety, supporting its use alongside cataract surgery and potentially expanding its market. Investors may view the data as a catalyst for further adoption and revenue growth of the product.
Key facts
- 1The trial randomized 149 eyes, with 74 assigned to iDose TR plus cataract surgery and 75 to cataract surgery alone. investing.com
- 2At month 3, the iDose TR group achieved a mean diurnal IOP reduction of 11.1 mmHg from baseline. investing.com
- 3The surgery‑alone group achieved a mean diurnal IOP reduction of 7.4 mmHg from baseline. investing.com
- 4The incremental IOP reduction for iDose TR versus surgery alone was 3.6 mmHg (p<0.0001). investing.com
- 5No treatment‑related adverse events of corneal endothelial cell loss, cystoid macular edema, or serious corneal events were reported through three months. investing.com
- 6Glaukos began commercial launch activities for iDose TR in 2024. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.